ConductScience.org, home

Paper33211112

Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.

Cullinane C and 7 others. JAMA Netw Open, 2020. Cited by 119 papers, by iCite.

Cite this record

ConductScience Library. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis. Papers, record 33211112. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33211112

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
PubMed
Journal
JAMA Netw Open
PubMed
Year
2020
PubMed
Publication types
Journal Article, Meta-Analysis, Systematic Review
PubMed
Citations, by iCite
119
iCite
Relative citation ratio, by iCite
4.68
iCite
Revised in PubMed
2021-01-18
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cullinane CCarolyn
2Fleming CChristina
3O'Leary DPDonal Peter
4Hassan FFara
5Kelly LLouise
6O'Sullivan MJMartin J
7Corrigan MAMark Antony
8Redmond HPHenry Paul

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Circulating Tumor DNAMajor topic
Aftercare
Disease-Free Survival
Female
Humans
Neoplasm Metastasis
Neoplasm Recurrence, Local
Neoplasm Staging
Observational Studies as Topic
Precision Medicine
Prognosis
Progression-Free Survival
Prospective Studies
Retrospective Studies

Source PubMed

Download CSV of topics

References36

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130588246Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer.J Cancer2018https://conductscience.org/library/papers/30588246PubMed
230889786Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology.J Clin Med2019https://conductscience.org/library/papers/30889786PubMed
330654364Potential of Liquid Biopsies for Breast Cancer Screening, Diagnosis, and Response to Treatment.Oncology2019https://conductscience.org/library/papers/30654364PubMed
429595655The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis.Medicine (Baltimore)2018https://conductscience.org/library/papers/29595655PubMed
520652370Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.Eur J Epidemiol2010https://conductscience.org/library/papers/20652370PubMed
631391323Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.Sci Transl Med2019https://conductscience.org/library/papers/31391323PubMed
730833418Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer.Cold Spring Harb Mol Case Stud2019https://conductscience.org/library/papers/30833418PubMed
828392479Circulating Tumor DNA as Biomarkers for Cancer Detection.Genomics Proteomics Bioinformatics2017https://conductscience.org/library/papers/28392479PubMed
926786933Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.J Clin Oncol2016https://conductscience.org/library/papers/26786933PubMed
1027532364Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.JAMA Oncol2016https://conductscience.org/library/papers/27532364PubMed
1131241775Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer.Int J Cancer2020https://conductscience.org/library/papers/31241775PubMed
1231183188Feasibility and clinical value of circulating tumor DNA testing in patients with gastric adenocarcinomas.J Gastrointest Oncol2019https://conductscience.org/library/papers/31183188PubMed
1315734995Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients.Cancer Res2005https://conductscience.org/library/papers/15734995PubMed
1423974828The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.Breast Cancer Res Treat2013https://conductscience.org/library/papers/23974828PubMed
1514633683DNA methylation in serum of breast cancer patients: an independent prognostic marker.Cancer Res2003https://conductscience.org/library/papers/14633683PubMed
1629572011Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker.Cancer Genet2018https://conductscience.org/library/papers/29572011PubMed
1727091708Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.J Clin Oncol2016https://conductscience.org/library/papers/27091708PubMed
1812473587Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival.Clin Cancer Res2002https://conductscience.org/library/papers/12473587PubMed
1927144417The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring.Expert Rev Mol Diagn2016https://conductscience.org/library/papers/27144417PubMed
2025987569Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease.EMBO Mol Med2015https://conductscience.org/library/papers/25987569PubMed

See all 36 referencesDownload CSV of references

Cited by80

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 119 citations.

PMIDTitleJournalYearIn PapersSource
42737612Circulating Tumor DNA and Circulating Tumor Cells in Liquid Biopsy as Post-Treatment Prognostic Biomarkers in Early Breast Cancer: A Systematic Review and Meta-Analysis.Int J Mol Sci2026https://conductscience.org/library/papers/42737612PubMed
42727049Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab.JCO Precis Oncol2026https://conductscience.org/library/papers/42727049PubMed
42653691Antibody-Drug Conjugates Targeting HER2 and Trop-2: A New Force in Precision Treatment for Solid Tumors.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42653691PubMed
42455255Optimizing Extended Adjuvant Endocrine Therapy in Early HR+/HER2- Breast Cancer: The Emerging Role of Genomic Assays and ctDNA MRD.Adv Ther2026https://conductscience.org/library/papers/42455255PubMed
42200016Predicting the prognosis of breast cancer patients by using nutrition-based index: a systematic review and meta-analysis.Front Oncol2026https://conductscience.org/library/papers/42200016PubMed
42003932Biological basis and clinical translation prospects of circulating cell-free DNA in precision management of breast cancer (Review).Oncol Lett2026https://conductscience.org/library/papers/42003932PubMed
41951687Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial.NPJ Breast Cancer2026https://conductscience.org/library/papers/41951687PubMed
41827756From Feasibility to Individualization: Surgery for Breast Cancer Liver and Lung Metastases.Cancers (Basel)2026https://conductscience.org/library/papers/41827756PubMed
41710655Accuracy of ctDNA-based minimal residual disease detection in predicting postoperative recurrence of breast cancer: a meta-analysis.Front Oncol2026https://conductscience.org/library/papers/41710655PubMed
41543393ctDNA Detected after Neoadjuvant Therapy for HER2-Positive Breast Cancer Is Associated with Inferior Outcomes and May Inform Adjuvant Therapy.Cancer Res Commun2026https://conductscience.org/library/papers/41543393PubMed
40844552The assessment of breast cancer biomarkers in diagnosis, prognosis and treatment monitoring: integrated analysis.J Cancer Res Clin Oncol2025https://conductscience.org/library/papers/40844552PubMed
40742511Was kommt nach CDK4/6-Inhibition? Perspektiven beim fortgeschrittenen Mammakarzinom.Wien Klin Wochenschr2025https://conductscience.org/library/papers/40742511PubMed
40681188Preoperative partial breast reirradiation and repeat breast-conserving surgery in patients with recurrent breast cancer: the prospective single-arm REPEAT trial - a study protocol.BMJ Open2025https://conductscience.org/library/papers/40681188PubMed
40586858Liquid biopsy in breast cancer: clinical implications of ctDNA and CTCs in diagnosis, treatment and monitoring.Mol Cell Biochem2025https://conductscience.org/library/papers/40586858PubMed
40428282The Application of Circulating Tumour DNA (ctDNA) in the Diagnosis, Prognosis, and Treatment Monitoring of Gynaecological and Breast Cancers (Review).Diagnostics (Basel)2025https://conductscience.org/library/papers/40428282PubMed
40295143Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study.J Immunother Cancer2025https://conductscience.org/library/papers/40295143PubMed
40146490Circulating Tumor DNA in High-Risk Stage II/III Cutaneous Melanoma: A Feasibility Study.Ann Surg Oncol2025https://conductscience.org/library/papers/40146490PubMed
40055250Development of a prediction model for ctDNA detection (Cir-Predict) in breast cancer.Breast Cancer Res Treat2025https://conductscience.org/library/papers/40055250PubMed
39896816The prognostic value of circulating tumor DNA in malignant melanoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.Front Immunol2024https://conductscience.org/library/papers/39896816PubMed
39844103Multiple time points for detecting circulating tumor DNA to monitor the response to neoadjuvant therapy in breast cancer: a meta-analysis.BMC Cancer2025https://conductscience.org/library/papers/39844103PubMed

See all 80 cited byDownload CSV of cited by

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33211112

GET https://conductscience.org/api/papers/v1/33211112/references?page=2